Table 2 Clinical and imaging feature of the patients with the hepatic liver lesion
H-MCNs (n = 29) | HSC (n = 75) | p-value | |
|---|---|---|---|
Demographics | |||
Age, mean(SD), year | 0.068 | ||
> 60 | 9 (31.0) | 40 (53.3) | |
≤ 60 | 20 (79.0) | 35 (46.7) | |
Sex, n (%) | 0.463 | ||
Female | 20 (69.0) | 57 (76.0) | |
Male | 9 (31) | 25 (24) | |
Symptom, n (%) | |||
Abdominal pain | 14 (48.3) | 19 (25.3) | 0.024 |
Abdominal fullness | 7 (24.1) | 10 (13.3) | 0.181 |
Fever | 4 (13.8) | 0 (0) | 0.005 |
Jaundice | 2 (6.9) | 0 (0) | 0.076 |
Weight loss | 1 (3.4) | 0 (0) | 0.275 |
Duration of the symptom (month) | 1 (0.133–240) | 60 (0.1–360) | < 0.001 |
Liver function | |||
AST (IQR), U/l | 23 (13–38) | 20 (18–23) | 0.273 |
ALT (IQR), U/l | 20 (13.5–31.5) | 17 (14–22) | 0.101 |
Total bilirubin (IQR), mg/dl | 13.4 (11.2–16.2) | 12.3 (10–16) | 0.730 |
Serum tumor markers | |||
CA 19–9 (U/mL), n (%) | 0.001 | ||
> 20 | 18 (64.3) | 15 (27.3) | |
≤ 20 | 10 (35.7) | 40 (72.7) | |
CEA (ng/mL), n (%) | 0.469 | ||
> 5 | 2 (7.1) | 2 (2.7) | |
≤ 5 | 26 (92.9) | 54 (72.0) | |
CA 12–5 (U/mL), n (%) | 0.117 | ||
> 20 | 6 (20.7) | 5 (9.1) | |
≤ 20 | 22 (75.9) | 50 (90.9) | |
AFP (ng/ml), n (%) | 0.598 | ||
> 10 | 2 (7.1) | 2 (3.6) | |
≤ 10 | 26 (92.9) | 54 (96.4) | |
Imaging feature†, n (%) | |||
Biliary ductal dilation | 17 (58.6) | 4 (5.3) | < 0.001 |
Multilocular cyst | 17 (58.6) | 26 (83.9) | 0.109 |
Enhancement after contrast | 20 (69.0) | 11 (14.7) | < 0.001 |
Septa | 13 (44.8) | 12 (16.0) | 0.002 |
Calcification | 2 (6.9) | 12 (16.0) | 0.223 |
Cyst size (cm), median (IQR) | 8.5 (3.7–12.3) | 9.1 (7.8–11.0) | 0.131 |
Location of the cyst, n (%) | < 0.001 | ||
Left | 23 (79.3) | 22 (29.2) | |
Right | 3 (10.3) | 39 (58) | |
Both | 3 (10.3) | 14 (18.7) |